Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: An initial experience in Taiwan

摘要: Abstract Background Acute rejection is the major cause of graft loss in renal transplantation. Sirolimus (rapamycin) inhibits effects cytokines on T and B cells; therefore, it provides prophylaxis against acute rejection. This open-label trial assessed incidence biopsy-confirmed episodes, variation function, as well patient survival rates up to 12 months posttransplantation when using sirolimus combination with cyclosporine prednisolone immunosuppressants. Methods Ten kidney transplant recipients received 2 mg daily after a 6-mg loading dose. Doses were then adjusted keep whole-blood trough level between 5 20 mg/mL. All patients prednisolone. Results At transplantation, 90% 90%, respectively. One died at due sepsis functioning graft. The mean serum creatinine levels 1, 3, 6 1.59 mg/dL, 1.71 1.65 ml/dL, There was no episode within months. Conclusions significantly protected from for 1 year follow-up.